Daily Stock Analysis, GRFS, Grifols SA, priceseries

Grifols SA. Daily Stock Analysis
Stock Information
Open
22.15
Close
22.12
High
22.24
Low
21.96
Previous Close
22.15
Daily Price Gain
-0.03
YTD High
22.46
YTD High Date
Jul 18, 2019
YTD Low
17.44
YTD Low Date
May 31, 2019
YTD Price Change
4.21
YTD Gain
23.52%
52 Week High
22.46
52 Week High Date
Jul 18, 2019
52 Week Low
17.19
52 Week Low Date
Oct 24, 2018
52 Week Price Change
1.13
52 Week Gain
5.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 22. 2017
17.05
May 11. 2017
20.23
35 Trading Days
18.63%
Link
LONG
Dec 21. 2017
21.58
Jan 18. 2018
23.51
17 Trading Days
8.95%
Link
LONG
May 4. 2018
20.36
May 24. 2018
21.82
14 Trading Days
7.17%
Link
LONG
Oct 26. 2018
19.13
Nov 12. 2018
20.48
11 Trading Days
7.09%
Link
LONG
Jun 6. 2019
18.55
Jul 12. 2019
21.39
25 Trading Days
15.30%
Link
Company Information
Stock Symbol
GRFS
Exchange
NasdaqGS
Company URL
http://www.grifols.com
Company Phone
212-969-3335
CEO
Raimon Grifols Roura
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001438569
About

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Description

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.